Elevance Health, Inc. $ELV Shares Sold by Hunter Perkins Capital Management LLC

Hunter Perkins Capital Management LLC reduced its position in Elevance Health, Inc. (NYSE:ELV) by 19.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 16,598 shares of the company’s stock after selling 3,983 shares during the quarter. Elevance Health comprises about 1.3% of Hunter Perkins Capital Management LLC’s holdings, making the stock its 22nd largest position. Hunter Perkins Capital Management LLC’s holdings in Elevance Health were worth $5,818,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its stake in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the period. Rossby Financial LCC increased its stake in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Activest Wealth Management increased its stake in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after acquiring an additional 34 shares during the period. Motco raised its holdings in Elevance Health by 334.8% during the third quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 77 shares in the last quarter. Finally, True Wealth Design LLC raised its holdings in Elevance Health by 431.8% during the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock worth $38,000 after purchasing an additional 95 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

Elevance Health stock opened at $286.23 on Friday. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $322.20 and its 200 day simple moving average is $332.71. The firm has a market capitalization of $63.17 billion, a PE ratio of 11.39, a P/E/G ratio of 1.57 and a beta of 0.51.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were paid a dividend of $1.72 per share. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. Elevance Health’s dividend payout ratio is 27.39%.

Wall Street Analyst Weigh In

ELV has been the topic of a number of analyst reports. Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective on the stock. in a report on Tuesday, February 3rd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Jefferies Financial Group reduced their price target on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a report on Friday, January 30th. Wells Fargo & Company decreased their price target on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Finally, Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.